Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
394.3 USD | +0.20% | -0.57% | -3.10% |
Apr. 18 | Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain | MT |
Apr. 17 | UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.10% | 102B | |
+2.11% | 96.07B | |
-1.80% | 21.66B | |
-17.75% | 20.77B | |
-6.91% | 18.53B | |
-42.00% | 16.91B | |
-28.19% | 13.79B | |
+0.18% | 13.33B | |
+19.90% | 10.94B | |
-23.23% | 8.57B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals : RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $242 From $262, Maintains Outperform Rating